Literature DB >> 3514793

Activation of complement by myelin: identification of C1-binding proteins of human myelin from central nervous tissue.

P Vanguri, M L Shin.   

Abstract

Myelin isolated from central nervous tissue activates the classic pathway of complement by directly activating C1. Activation of C1 can proceed to form membrane attack complex, C5b-9, in the myelin. Such an interaction between myelin and complement may be important in diseases involving myelin damage, in view of the role of complement in membrane attack and inflammation. To identify the C1-activating protein, myelin was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. The blots were incubated with C1 or with whole serum complement, followed by immunostaining for C1 or C3, respectively. A duplicate strip was stained with amido black or anti-myelin antibody to visualize the myelin proteins. The results showed that two major protein bands were capable of activating C1. An approximately 56-58-kilodalton band comigrated with the W2 protein and an approximately 45-47-kilodalton band migrated along with, but slightly behind, the W1 Wolfgram doublet.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514793     DOI: 10.1111/j.1471-4159.1986.tb01773.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro.

Authors:  W Brück; R L Friede
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody.

Authors:  D R Wren; M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus.

Authors:  Haolong Cong; Yue Jiang; Po Tien
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis.

Authors:  M J Walsh; J M Murray
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

6.  The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.

Authors:  Craig S Clements; Hugh H Reid; Travis Beddoe; Fleur E Tynan; Matthew A Perugini; Terrance G Johns; Claude C A Bernard; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

7.  Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.

Authors:  M G Wing; J Zajicek; D J Seilly; D A Compston; P J Lachmann
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

8.  Huntington's Disease: An Immune Perspective.

Authors:  Annapurna Nayak; Rafia Ansar; Sunil K Verma; Domenico Marco Bonifati; Uday Kishore
Journal:  Neurol Res Int       Date:  2011-08-24

Review 9.  Contribution of the Degeneration of the Neuro-Axonal Unit to the Pathogenesis of Multiple Sclerosis.

Authors:  Hannah E Salapa; Sangmin Lee; Yoojin Shin; Michael C Levin
Journal:  Brain Sci       Date:  2017-06-18

Review 10.  The Potential Contribution of Dysfunctional RNA-Binding Proteins to the Pathogenesis of Neurodegeneration in Multiple Sclerosis and Relevant Models.

Authors:  Cole D Libner; Hannah E Salapa; Michael C Levin
Journal:  Int J Mol Sci       Date:  2020-06-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.